TY - JOUR
T1 - Transcriptional Inhibitors Identified in a 160,000-Compound Small-Molecule DUX4 Viability Screen
AU - Choi, Si Ho
AU - Bosnakovski, Darko
AU - Strasser, Jessica M.
AU - Toso, Erik A.
AU - Walters, Michael A.
AU - Kyba, Michael
N1 - Publisher Copyright:
© Society for Laboratory Automation and Screening.
PY - 2016/8/1
Y1 - 2016/8/1
N2 - Facioscapulohumeral muscular dystrophy is a genetically dominant, currently untreatable muscular dystrophy. It is caused by mutations that enable expression of the normally silent DUX4 gene, which encodes a pathogenic transcription factor. A screen based on Tet-on DUX4-induced mouse myoblast death previously uncovered compounds from a 44,000-compound library that protect against DUX4 toxicity. Many of those compounds acted downstream of DUX4 in an oxidative stress pathway. Here, we extend this screen to an additional 160,000 compounds and, using greater stringency, identify a new set of DUX4-protective compounds. From 640 hits, we performed secondary screens, repurchased 46 of the most desirable, confirmed activity, and tested each for activity against other cell death-inducing insults. The majority of these compounds also protected against oxidative stress. Of the 100 repurchased compounds identified through both screens, only SHC40, 75, and 98 inhibited DUX4 target genes, but they also inhibited dox-mediated DUX4 expression. Using a target gene readout on the 640-compound hit set, we discovered three overlooked compounds, SHC351, 540, and 572, that inhibit DUX4 target gene upregulation without nonspecific effects on the Tet-on system. These novel inhibitors of DUX4 transcriptional activity may thus act on pathways or cofactors needed by DUX4 for transcriptional activation in these cells.
AB - Facioscapulohumeral muscular dystrophy is a genetically dominant, currently untreatable muscular dystrophy. It is caused by mutations that enable expression of the normally silent DUX4 gene, which encodes a pathogenic transcription factor. A screen based on Tet-on DUX4-induced mouse myoblast death previously uncovered compounds from a 44,000-compound library that protect against DUX4 toxicity. Many of those compounds acted downstream of DUX4 in an oxidative stress pathway. Here, we extend this screen to an additional 160,000 compounds and, using greater stringency, identify a new set of DUX4-protective compounds. From 640 hits, we performed secondary screens, repurchased 46 of the most desirable, confirmed activity, and tested each for activity against other cell death-inducing insults. The majority of these compounds also protected against oxidative stress. Of the 100 repurchased compounds identified through both screens, only SHC40, 75, and 98 inhibited DUX4 target genes, but they also inhibited dox-mediated DUX4 expression. Using a target gene readout on the 640-compound hit set, we discovered three overlooked compounds, SHC351, 540, and 572, that inhibit DUX4 target gene upregulation without nonspecific effects on the Tet-on system. These novel inhibitors of DUX4 transcriptional activity may thus act on pathways or cofactors needed by DUX4 for transcriptional activation in these cells.
KW - DUX4
KW - facioscapulohumeral muscular dystrophy
KW - high-throughput screening
KW - small-molecule inhibitors
UR - http://www.scopus.com/inward/record.url?scp=84979248502&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84979248502&partnerID=8YFLogxK
U2 - 10.1177/1087057116651868
DO - 10.1177/1087057116651868
M3 - Article
C2 - 27245141
AN - SCOPUS:84979248502
SN - 1087-0571
VL - 21
SP - 680
EP - 688
JO - Journal of Biomolecular Screening
JF - Journal of Biomolecular Screening
IS - 7
ER -